Gate2Brain obtains over €700,000 in CDTI Multipaís funding to advance a novel therapy against pediatric brain tumors in collaboration with India

• Gate2Brain has secured funding from the Centro para el Desarrollo Tecnológico Industrial (CDTI Innovación), a key milestone in advancing its CNS drug delivery platform.

• Spain and India are collaborating to accelerate the preclinical and clinical development of G2B-002, a novel therapy for high-grade pediatric brain tumors.

• This funding will support the completion of regulatory preclinical studies and progress toward the start of clinical trials in early 2028.

Gate2Brain , a spin-off from IRB Barcelona , the Universitat de Barcelona , and Hospital Sant Joan de Déu Barcelona , has been awarded funding from the Centro para el Desarrollo Tecnológico Industrial (CDTI Innovación) under the Multipaís 2024 program. This financial support represents a significant milestone for Gate2Brain , reinforcing its innovative approach to drug delivery for central nervous system (CNS) diseases.

This funding is part of Spain’s Recovery, Transformation, and Resilience Plan, within the framework of the PERTE Vanguard Health initiative, which supports the development of pioneering health technologies with the potential to transform patient care. The project is also backed by the Ministry of Science and Innovation and the European Union (NextGenerationEU), reflecting the strategic importance of this research.

An International Collaboration for a High-Impact Therapy

With the support of the CDTI Multipaís program, Gate2Brain is driving an international initiative with Spain and India working together to accelerate the clinical development of G2B-002. This therapy is specifically designed for the treatment of high-grade pediatric brain tumors and has already demonstrated:

• Effective blood–brain barrier penetration through Gate2Brain’s proprietary peptide shuttle technology.

• Promising anticancer activity in preclinical models.

• Good tolerability in early studies, setting the stage for further clinical validation.

 This funding will allow Gate2Brain to finalize the regulatory preclinical development of G2B-002 and advance towards a clinical trial in pediatric patients with diffuse midline glioma (DMG) by the end of 2027.

Transforming Pediatric Oncology and CNS Drug Delivery

Gate2Brain ’s groundbreaking peptide-based platform represents a paradigm shift in non-invasive and efficient drug transport across the blood–brain barrier, a major challenge in CNS drug development. While the initial focus is on pediatric brain tumors, this technology holds significant potential for broader applications in the treatment of other CNS diseases.

About Gate2Brain

Gate2Brain is a technology platform spin off from IRB Barcelona , the Universitat de Barcelona ,and the Hospital Sant Joan de Déu Barcelona , founded in 2020. Gate2Brain uses its proprietary peptide-based technology to cross biological barriers, such as the blood–brain barrier, to improve drug delivery to the brain and reduce side effects.  With a first asset in pediatric brain tumors the present work demonstrates the expansion of the potential use of their technology.

The company has received support from institutions including Fundación Botín (Mind the Gap), Banco Sabadell (BStartup Health), @CDTI_innovacion Ministerio de Ciencia e Innovación, European Union (Next Generation EU), the EIC - European Innovation Council (EIC Accelerator), Startup Capital d’ACCIÓ, and CaixaResearch Consolidate de la Fundación ”la Caixa”

Gate2Brain envisions improving patients' quality of life through technology that enhances drug delivery efficiency.